Companies · Pharmaceuticals

VersaPeutics, Inc.

SAN DIEGO · Pharmaceuticals

Diligence memoA one-page analyst read on VersaPeutics, Inc. — recommendation, valuation, rhythm, risks.
$3.8M
Total raised · real
3
Rounds
32.0×
Latest step-up
Top 64%
Sector rank · raised
Seed
Latest stage · inferred · Wed Aug 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

VersaPeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.02× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era.
Dormant
  • Last raise 7.9 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

VersaPeutics, Inc. is one of 1610 Pharmaceuticals companies tracked from SAN DIEGO. By capital raised it ranks in the long tail (ahead of 37% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
4
Investors (latest)
2017
Year incorporated
2018-08-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2017-09-20 Raised $450K (real) Modeled valuation $21M (est)$450K$21MPre-Seed2017Pre-Seed · 2018-07-02 Raised $100K (real) Modeled valuation $4.7M (est)$100K$4.7MPre-Seed2018Seed · 2018-08-15 Raised $3.2M (real) Modeled valuation $122M (est)$3.2M$122MSeed2018+$100K+$3.2MCumulative $3.8M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$450K · 2017
Pre-Seed extension$100K · 2018
Seed$3.2M · 2018

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$121.7M
Base estimate est.
$2.4M
Conservative case
$955.1M
Upside case
$16.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $21.3M · 2017-09-202017Pre-Seed · modeled $4.7M · 2018-07-02Seed · modeled $121.7M · 2018-08-152018
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
7.9 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
5 mo
Avg between rounds
$4.2M/yr
Capital velocity
8.8 yr
On record since
2017
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.5× of median
This company$3.8M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.9× above median
This company$3.2M
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 1.6× above median
This company$121.7M
Sector median$76.1M

Raised more than 37% of sector peers (real $). Modeled value above 58% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #10 of 71.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0MCapital raised (log)Chase Therapeutics Corp · Seed Raised $5.3M · modeled $152.2M (est)Acura Pharmaceuticals, Inc · Seed Raised $4.0M · modeled $152.2M (est)Paragon Biosciences Skyline Capital, LLC · Seed Raised $4.0M · modeled $150.9M (est)Saghmos Therapeutics, Inc. · Seed Raised $3.5M · modeled $133.1M (est)Phoenix PharmaLabs Inc · Seed Raised $3.5M · modeled $133.1M (est)Immucell Corp /De/ · Seed Raised $3.5M · modeled $131.8M (est)Madrigal Pharmaceuticals, Inc. · Seed Raised $3.4M · modeled $128.4M (est)Hydropothecary Corp · Seed Raised $3.3M · modeled $124.6M (est)SapVax, LLC · Seed Raised $3.3M · modeled $123.6M (est)Westwood Life Sciences, Llc · Seed Raised $3.1M · modeled $116.3M (est)Har-Kcy, Llc · Seed Raised $3.0M · modeled $114.3M (est)VersaPeutics, Inc. (this company) Raised $3.8M · modeled $121.7M (est)VersaPeutics, Inc.
CompanyStageRaised · realValue · estvs peer med.
Chase Therapeutics CorpSeed$5.3M$152.2M2.52×
Acura Pharmaceuticals, IncSeed$4.0M$152.2M2.52×
Paragon Biosciences Skyline Capital, LLCSeed$4.0M$150.9M2.50×
Saghmos Therapeutics, Inc.Seed$3.5M$133.1M2.21×
Phoenix PharmaLabs IncSeed$3.5M$133.1M2.21×
Immucell Corp /De/Seed$3.5M$131.8M2.19×
Madrigal Pharmaceuticals, Inc.Seed$3.4M$128.4M2.13×
Hydropothecary CorpSeed$3.3M$124.6M2.07×
SapVax, LLCSeed$3.3M$123.6M2.05×
VersaPeutics, Inc. this companySeed$3.8M$121.7M2.02×
Westwood Life Sciences, LlcSeed$3.1M$116.3M1.93×
Har-Kcy, LlcSeed$3.0M$114.3M1.90×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$450K2017-09-20$2.5M$21.3M90%
Pre-Seed$100K2018-07-02$556K$4.7M90%
Seed$3.2M2018-08-15$16.0M$121.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$450K2017-09-20
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Pre-Seed$100K2018-07-02
    • Raised 9 mo later, in step with the ~13 mo sector norm.
    • Round 4.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  3. Seed$3.2M2018-08-15
    • Came back fast: 1 mo vs the ~13 mo sector norm.
    • Round 32.0× larger than the prior — scaling up.
    • 4 investors on this round.
Intelligence
2019 ~Q1
Modeled next raise · ~5mo cadence
$9.6M
Modeled next size est.range $6.2M$15.4M
32.0×
Last step-up
$4.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Haipeng Cheng1 other2017-09
Yimin Zou1 other2017-09
Haipeng Chen2018-07
Registry & provenance

VersaPeutics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1731409
SEC CIK
2017
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
VersaChem, Inc.PharmaceuticalsSeed$1.5M$57.1Mnetwork1 shared operator · same sector · same stage
Aggamin Pharmaceuticals, LLCPharmaceuticalsSeed$3.7M$141.6Msame sector · same stage
Sequoia Pharmaceuticals IncPharmaceuticalsSeed$3.8M$144.6Msame sector · same stage
Femta Pharmaceuticals, Inc.PharmaceuticalsSeed$3.7M$83.7Msame sector · same stage
Akorn IncPharmaceuticalsSeed$3.8M$63.4Msame sector · same stage
Assured Pharma, Inc.PharmaceuticalsSeed$3.9M$147.4Msame sector · same stage
Abeona Therapeutics LLCPharmaceuticalsSeed$3.6M$137.4Msame sector · same stage
Evestra IncPharmaceuticalsSeed$3.6M$68.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
VersaChem, Inc.PharmaceuticalsSeed$57.1M91%
Laurent Pharmaceuticals Inc.PharmaceuticalsSeed$53.7M83%
Pharmaceutics International, Inc.PharmaceuticalsSeries D+$123.9M83%
Harmony Biosciences II, Inc.PharmaceuticalsSeries D+$1.8B83%
Variant Pharmaceuticals, Inc.PharmaceuticalsSeries B$7.2M81%
Shuttle Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$7.0M81%
Owp Pharmaceuticals, Inc.PharmaceuticalsSeed$6.6M81%
Sancilio Pharmaceuticals Company, Inc.PharmaceuticalsSeries A$154.9M81%
Frequently asked
How much funding has VersaPeutics, Inc. raised?
VersaPeutics, Inc. has raised approximately $3.8M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is VersaPeutics, Inc.'s estimated valuation?
Provath's modeled valuation for VersaPeutics, Inc. is approximately $121.7M (modeled range $2.4M–$955.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is VersaPeutics, Inc. at?
VersaPeutics, Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Wed Aug 15.
What does VersaPeutics, Inc. do and where is it based?
VersaPeutics, Inc. operates in the Pharmaceuticals sector, based in SAN DIEGO.
Explore related

See where VersaPeutics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at VersaPeutics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.